C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
The product is expected to be launched in FY25
Almost 300 million people globally have chronic hepatitis B
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Product will be manufactured at the company's facility in Bengaluru
Subscribe To Our Newsletter & Stay Updated
